LifeX PitchCraft

​PitchCraft is where founders get to workshop their business narrative with a room full of veterans who've built, funded, and scaled companies in this space. This new generation of life sciences companies is actively looking to connect with local investors, operators, and domain experts who know their space.

​Each session brings together a small, curated group of experts, industry partners, and experienced entrepreneurs to engage directly with 2–3 early-stage founders, not as an audience, but as a room.

• ​Experts will hear live pitches and ask the questions that matter.

• ​Founders will receive the kind of candid, experienced perspective that genuinely moves the needle for companies at this stage. 

​It's a two-hour commitment with an outsized return: a close look at emerging life sciences companies in Western PA, and the chance to be a meaningful part of their progress.

Attendance is invite-only and kept intentionally small so that every voice in the room carries weight.

​May 8 Featured Companies:

​Accelowave
Myoverse
Vitalight Medical Inc.

​Agenda:
8:30 - 8:50 AM: Welcome
8:50 - 9:10 AM: Accelowave Pitch
9:10 - 9:30 AM: Myoverse Pitch
9:30 - 9:50 AM: Vitalight Medical Inc. Pitch
9:50 - 10:30 AM: General feedback, wrap up, and networking

​Company Information:

​Accelowave
Accelowave Technologies is developing the Aspirometer, an AI-powered, noninvasive device that detects aspiration risk at the point of care for which current bedside screening methods are only about 50% accurate. The Aspirometer uses a small throat-mounted sensor and machine learning algorithms trained on thousands of swallows to provide an objective, real-time assessment of swallowing safety.

​Myoverse
MyoVerse is a wireless, body-adaptive EMG patch that captures high-density muscle data in real time — powering actionable insights that drive measurably better clinical outcomes.

​Vitalight Medical Inc.
Vitalight Medical Inc. produces an optical blood pressure cuff that provides more accurate blood pressure measurements than existing non-invasive solutions. Crucially, our device remains accurate in populations presenting altered cardiac pulsatility, such as artificial heart patients for whom existing solutions fail.